

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4190917/julie-le-naour-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12 papers	305 citations	8 h-index	15 g-index
15 ext. papers	468 ext. citations	9.4 avg, IF	3.99 L-index

#	Paper	IF	Citations
12	Gut Microbiota-Stimulated Innate Lymphoid Cells Support α -Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. <i>Cell Metabolism</i> , 2018 , 28, 557-572.e6	24.6	67
11	Trial watch: STING agonists in cancer therapy. <i>Oncolimmunology</i> , 2020 , 9, 1777624	7.2	61
10	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolimmunology</i> , 2020 , 9, 1777625	7.2	45
9	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolimmunology</i> , 2019 , 8, e1657375	7.2	38
8	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>Oncolimmunology</i> , 2020 , 9, 1796002	7.2	25
7	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolimmunology</i> , 2020 , 9, 1771143	7.2	23
6	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
5	Trial watch: intratumoral immunotherapy. <i>Oncolimmunology</i> , 2021 , 10, 1984677	7.2	7
4	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	4
3	No impact of cancer and plague-relevant polymorphisms on COVID-19. <i>Oncolimmunology</i> , 2020 , 9, 1857112	7.2	2
2	Improved Swiss-rolling method for histological analyses of colon tissue.. <i>MethodsX</i> , 2022 , 9, 101630	1.9	1
1	A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients.. <i>Oncolimmunology</i> , 2022 , 11, 2059878	7.2	0